Skip to content

Kathryn Ledden

3 papers in the library · 86 citations · publishing 2021-2026

Papers

Sort Most recent Most cited

GH001 vs Placebo in Patients With Treatment-Resistant Depression

JAMA Psychiatry March 25, 2026 Wiesław Jerzy Cubała, Malek Bajbouj, Michael Bauer et al. 3 citations

Importance: Few pharmacotherapies are approved for treatment-resistant depression, and many patients do not achieve remission following treatment with those therapies. Objective: To examine the efficacy and safety of single-day treatment with a synthetic formulation of inhaled mebufotenin (GH001) vs placebo in patients with treatment-resistant depression. Design, Setting, and Participants: This...

Narrating the psychoneuroimmunomodulatory properties of serotonin 5-HT2A receptor psychedelics from a transdiagnostic perspective.

Acta Neuropsychiatrica July 25, 2025 Guillaume Thuery, Christopher Sheridan, Patricia Iusan et al. 4 citations

By synthesising findings from both clinical and preclinical research, this review aims to provide an understanding of the interplay between 5-HT2A receptor psychedelics and the immune system and considers how their immunomodulatory effects associate with neuronal and behavioural changes. A PubMed literature search covering the past 30 years was conducted using keywords such as "5-HT2A...

Psychedelic perceptions: mental health service user attitudes to psilocybin therapy

Irish Journal of Medical Science (1971 -) June 15, 2021 Kate Corrigan, Maeve Haran, Conor Mccandliss et al. 79 citations

Abstract Introduction Despite the rapid advance of psychedelic science and possible translation of psychedelic therapy into the psychiatric clinic, very little is known about mental health service user attitudes. Objectives To explore mental health service user attitudes to psychedelics and psilocybin therapy. Methods A questionnaire capturing demographics, diagnoses, previous psychedelic and...